Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Other Non Operating Income: 2021-2025

Historic Other Non Operating Income for Intellia Therapeutics (NTLA) over the last 5 years, with Sep 2025 value amounting to $10.2 million.

  • Intellia Therapeutics' Other Non Operating Income rose 12.09% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.9 million, marking a year-over-year increase of 113.44%. This contributed to the annual value of $15.2 million for FY2024, which is 55.30% down from last year.
  • Per Intellia Therapeutics' latest filing, its Other Non Operating Income stood at $10.2 million for Q3 2025, which was up 16.15% from $8.7 million recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Other Non Operating Income high stood at $10.2 million for Q3 2025, and its period low was -$7.9 million during Q2 2024.
  • For the 3-year period, Intellia Therapeutics' Other Non Operating Income averaged around $6.8 million, with its median value being $8.7 million (2023).
  • In the last 5 years, Intellia Therapeutics' Other Non Operating Income plummeted by 2,306.02% in 2022 and then spiked by 464.03% in 2023.
  • Intellia Therapeutics' Other Non Operating Income (Quarterly) stood at -$822,000 in 2021, then slumped by 303.89% to -$3.3 million in 2022, then skyrocketed by 332.86% to $7.7 million in 2023, then fell by 2.35% to $7.5 million in 2024, then climbed by 12.09% to $10.2 million in 2025.
  • Its Other Non Operating Income stands at $10.2 million for Q3 2025, versus $8.7 million for Q2 2025 and $6.5 million for Q1 2025.